John Carl Panetta

List of Publications by Year
in descending order

157 papers	7,425 citations	47006 47 h-index	60623 81 g-index
161 all docs	161 docs citations	161 times ranked	8459 citing authors

#	Article	IF	Citations
1	Modeling immunotherapy of the tumor - immune interaction. Journal of Mathematical Biology, 1998, 37, 235-252.	1.9	699
2	Mrp4 Confers Resistance to Topotecan and Protects the Brain from Chemotherapy. Molecular and Cellular Biology, 2004, 24, 7612-7621.	2.3	403
3	Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical Effects. Journal of Clinical Oncology, 2009, 27, 5972-5978.	1.6	305
4	Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2014, 32, 949-959.	1.6	275
5	Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood, 2011, 117, 2340-2347.	1.4	219
6	A mathematical model of periodically pulsed chemotherapy: Tumor recurrence and metastasis in a competitive environment. Bulletin of Mathematical Biology, 1996, 58, 425-447.	1.9	197
7	Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice. Cancer Research, 2004, 64, 7491-7499.	0.9	193
8	Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood, 2013, 121, 898-904.	1.4	174
9	Population pharmacokinetic studies in pediatrics: Issues in design and analysis. AAPS Journal, 2005, 7, E475-E487.	4.4	163
10	Gefitinib Modulates the Function of Multiple ATP-Binding Cassette Transporters In vivo. Cancer Research, 2006, 66, 4802-4807.	0.9	154
11	Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. Cancer Cell, 2015, 28, 343-356.	16.8	145
12	Optimal Control Applied to Cell-Cycle-Specific Cancer Chemotherapy. SIAM Journal on Applied Mathematics, 2000, 60, 1059-1072.	1.8	130
13	Asparaginase May Influence Dexamethasone Pharmacokinetics in Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2008, 26, 1932-1939.	1.6	129
14	Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. Journal of Clinical Investigation, 2005, 115, 110-117.	8.2	129
15	NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nature Genetics, 2015, 47, 607-614.	21.4	126
16	High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer, 2004, 100, 1724-1733.	4.1	118
17	A mathematical model of cycle-specific chemotherapy. Mathematical and Computer Modelling, 1995, 22, 67-82.	2.0	115
18	Genetic Predictors of Interindividual Variability in Hepatic CYP3A4 Expression. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 1088-1099.	2.5	98

#	Article	IF	Citations
19	Optimal Control Applied to Competing Chemotherapeutic Cell-Kill Strategies. SIAM Journal on Applied Mathematics, 2003, 63, 1954-1971.	1.8	96
20	Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia, 2012, 26, 2303-2309.	7.2	93
21	A mathematical model of drug resistance: Heterogeneous tumors. Mathematical Biosciences, 1998, 147, 41-61.	1.9	90
22	Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood, 2006, 108, 3997-4002.	1.4	89
23	Plasma and Cerebrospinal Fluid Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420. Clinical Cancer Research, 2007, 13, 1511-1515.	7.0	89
24	UGT1A1 Promoter Genotype Correlates With SN-38 Pharmacokinetics, but Not Severe Toxicity in Patients Receiving Low-Dose Irinotecan. Journal of Clinical Oncology, 2007, 25, 2594-2600.	1.6	84
25	Phase I Trial, Pharmacokinetics, and Pharmacodynamics of Vandetanib and Dasatinib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma. Clinical Cancer Research, 2013, 19, 3050-3058.	7.0	82
26	Topotecan Central Nervous System Penetration Is Altered by a Tyrosine Kinase Inhibitor. Cancer Research, 2006, 66, 11305-11313.	0.9	79
27	A mathematical model of breast and ovarian cancer treated with paclitaxel. Mathematical Biosciences, 1997, 146, 89-113.	1.9	77
28	Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood, 2012, 119, 1658-1664.	1.4	77
29	In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression Profile. PLoS Medicine, 2008, 5, e83.	8.4	75
30	Cefixime Allows Greater Dose Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients With Refractory Solid Tumors. Journal of Clinical Oncology, 2006, 24, 563-570.	1.6	70
31	Comparison of Native E. coli and PEG Asparaginase Pharmacokinetics and Pharmacodynamics in Pediatric Acute Lymphoblastic Leukemia. Clinical Pharmacology and Therapeutics, 2009, 86, 651-658.	4.7	66
32	Molecular biology of breast metastasis The use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer. Breast Cancer Research, 2000, 2, 430-5.	5.0	64
33	Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors. Clinical Cancer Research, 2013, 19, 236-246.	7.0	64
34	Resumption of highâ€dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer, 2012, 118, 4321-4330.	4.1	62
35	MicroRNAs Form Triplexes with Double Stranded DNA at Sequence-Specific Binding Sites; a Eukaryotic Mechanism via which microRNAs Could Directly Alter Gene Expression. PLoS Computational Biology, 2016, 12, e1004744.	3.2	62
36	The SWI/SNF Chromatin-Remodeling Complex and Glucocorticoid Resistance in Acute Lymphoblastic Leukemia. Journal of the National Cancer Institute, 2008, 100, 1792-1803.	6.3	61

#	Article	IF	Citations
37	Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. Journal of Clinical Oncology, 2019, 37, 2051-2061.	1.6	61
38	Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics, 2014, 15, 1065-1078.	1.3	59
39	Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b. Cancer Research, 2015, 75, 2729-2736.	0.9	59
40	Using Pharmacokinetic and Pharmacodynamic Modeling and Simulation to Evaluate Importance of Schedule in Topotecan Therapy for Pediatric Neuroblastoma. Clinical Cancer Research, 2008, 14, 318-325.	7.0	55
41	Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood, 2005, 106, 1778-1785.	1.4	53
42	Tyrosine Kinase Inhibitor Enhances the Bioavailability of Oral Irinotecan in Pediatric Patients With Refractory Solid Tumors. Journal of Clinical Oncology, 2009, 27, 4599-4604.	1.6	53
43	Whole-Body Physiologically Based Pharmacokinetic Model for Nutlin-3a in Mice after Intravenous and Oral Administration. Drug Metabolism and Disposition, 2011, 39, 15-21.	3.3	53
44	Compartment-Specific Roles of ATP-Binding Cassette Transporters Define Differential Topotecan Distribution in Brain Parenchyma and Cerebrospinal Fluid. Cancer Research, 2009, 69, 5885-5892.	0.9	52
45	Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia. Journal of the National Cancer Institute, 2011, 103, 893-905.	6.3	50
46	Genomeâ€Wide Study Links PNPLA3 Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy. Clinical Pharmacology and Therapeutics, 2017, 102, 131-140.	4.7	50
47	Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer Chemotherapy and Pharmacology, 2003, 52, 435-441.	2.3	48
48	Total and Active Rabbit Antithymocyte Globulin (rATG;ThymoglobulinÂ®) Pharmacokinetics in Pediatric Patients Undergoing Unrelated Donor Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 274-278.	2.0	47
49	Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial. Lancet Infectious Diseases, The, 2020, 20, 964-975.	9.1	47
50	Modeling Mechanisms of In Vivo Variability in Methotrexate Accumulation and Folate Pathway Inhibition in Acute Lymphoblastic Leukemia Cells. PLoS Computational Biology, 2010, 6, e1001019.	3.2	46
51	Shortening Infusion Time for High-Dose Methotrexate Alters Antileukemic Effects: A Randomized Prospective Clinical Trial. Journal of Clinical Oncology, 2011, 29, 1771-1778.	1.6	45
52	Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nature Cancer, 2020, 1, 329-344.	13.2	44
53	A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemotherapy and Pharmacology, 2002, 50, 419-428.	2.3	43
54	Changes in body mass index, height, and weight in children during and after therapy for acute lymphoblastic leukemia. Cancer, 2018, 124, 4248-4259.	4.1	43

#	Article	IF	Citations
55	Pharmacogenetic Pathway Analysis of Irinotecan. Clinical Pharmacology and Therapeutics, 2008, 84, 393-402.	4.7	41
56	Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL. European Journal of Cancer, 2010, 46, 1848-1855.	2.8	39
57	Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter snp that alters PARP1 binding and SMARCB1 expression. Human Molecular Genetics, 2007, 16, 2261-2271.	2.9	38
58	Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice. Cancer Chemotherapy and Pharmacology, 2016, 77, 1039-1052.	2.3	38
59	Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28040.	1.5	38
60	Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity. Clinical Cancer Research, 2002, 8, 2423-9.	7.0	38
61	A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas. Mathematical Biosciences, 2003, 186, 29-41.	1.9	37
62	Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. Cancer Chemotherapy and Pharmacology, 2013, 72, 369-378.	2.3	36
63	A mathematical model of in vitro cancer cell growth and treatment with the antimitotic agent curacin A. Mathematical Biosciences, 2001, 170, 1-16.	1.9	35
64	Mechanistic mathematical modelling of mercaptopurine effects on cell cycle of human acute lymphoblastic leukaemia cells. British Journal of Cancer, 2006, 94, 93-100.	6.4	35
65	Pharmacokinetics and Pharmacodynamics of Oral Etoposide in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2003, 21, 1340-1346.	1.6	34
66	A logistic model of periodic chemotherapy. Applied Mathematics Letters, 1995, 8, 83-86.	2.7	30
67	Late-onset delayed excretion of methotrexate. Cancer Chemotherapy and Pharmacology, 2004, 54, 146-52.	2.3	30
68	Phase I and Pharmacokinetic Study of Topotecan Administered Orally Once Daily for 5 Days for 2 Consecutive Weeks to Pediatric Patients With Refractory Solid Tumors. Journal of Clinical Oncology, 2004, 22, 829-837.	1.6	29
69	P-Glycoprotein, but not Multidrug Resistance Protein 4, Plays a Role in the Systemic Clearance of Irinotecan and SN-38 in Mice. Drug Metabolism Letters, 2010, 4, 195-201.	0.8	29
70	Population PK/PD Model of Homocysteine Concentrations after High-Dose Methotrexate Treatment in Patients with Acute Lymphoblastic Leukemia. PLoS ONE, 2012, 7, e46015.	2.5	27
71	A simple mathematical model and alternative paradigm for certain chemotherapeutic regimens. Mathematical and Computer Modelling, 1995, 22, 49-60.	2.0	26
72	Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. Cancer Chemotherapy and Pharmacology, 2015, 75, 27-35.	2.3	25

#	Article	IF	Citations
73	The effect of body mass index at diagnosis on clinical outcome in children with newly diagnosed acute lymphoblastic leukemia. Blood Cancer Journal, 2017, 7, e531-e531.	6.2	25
74	Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2017, 23, 7558-7568.	7.0	23
75	Ketamine Pharmacokinetics and Pharmacodynamics Are Altered by P-Glycoprotein and Breast Cancer Resistance Protein Efflux Transporters in Mice. Drug Metabolism and Disposition, 2018, 46, 1014-1022.	3.3	23
76	Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2006, 57, 15-24.	2.3	22
77	Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Pharmacology and Therapeutics, 2018, 104, 575-583.	4.7	22
78	Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia. Journal of Pharmacokinetics and Pharmacodynamics, 2002, 29, 171-188.	1.8	21
79	Population Pharmacokinetic Analysis of Topotecan in Pediatric Cancer Patients. Clinical Cancer Research, 2007, 13, 6703-6711.	7.0	21
80	Phase I Study of the Tolerability and Pharmacokinetics of Palifermin in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1309-1314.	2.0	21
81	Bone mineral density in children with acute lymphoblastic leukemia. Cancer, 2018, 124, 1025-1035.	4.1	21
82	Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase. Cancer Chemotherapy and Pharmacology, 2014, 73, 1307-1313.	2.3	20
83	Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2016, 78, 1051-1058.	2.3	20
84	Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma. Cancer Chemotherapy and Pharmacology, 2016, 78, 1217-1223.	2.3	20
85	Predicting success of desensitization after pegaspargase allergy. Blood, 2020, 135, 71-75.	1.4	20
86	Formalizing an Integrative, Multidisciplinary Cancer Therapy Discovery Workflow. Cancer Research, 2013, 73, 6111-6117.	0.9	19
87	Population Pharmacokinetics of Vincristine Related to Infusion Duration and Peripheral Neuropathy in Pediatric Oncology Patients. Cancers, 2020, 12, 1789.	3.7	18
88	Pharmacogenomics of intracellular methotrexate polyglutamates in patientsâ€™ leukemia cells in vivo. Journal of Clinical Investigation, 2020, 130, 6600-6615.	8.2	18
89	A logistic model of periodic chemotherapy with drug resistance. Applied Mathematics Letters, 1997, 10, 123-127.	2.7	17
90	Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer. Cancer Chemotherapy and Pharmacology, 2004, 53, 253-260.	2.3	17

#	Article	IF	Citations
91	Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. Journal of Pediatric Hematology/Oncology, 2016, 38, 449-452.	0.6	17
92	Genetics of pleiotropic effects of dexamethasone. Pharmacogenetics and Genomics, 2017, 27, 294-302.	1.5	17
93	Pharmacokinetic basis for dosing highâ€dose methotrexate in infants and young children with malignant brain tumours. British Journal of Clinical Pharmacology, 2020, 86, 362-371.	2.4	17
94	A mathematical model of periodically pulsed chemotherapy: Tumor recurrence and metastasis in a competitive environment. Bulletin of Mathematical Biology, 1996, 58, 425-447.	1.9	15
95	Application of a highly specific and sensitive fluorescent HPLC method for topotecan lactone in whole blood. Biomedical Chromatography, 2009, 23, 707-713.	1.7	15
96	Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT. Bone Marrow Transplantation, 2012, 47, 1178-1185.	2.4	15
97	Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant. Drug Metabolism and Disposition, 2016, 44, 1116-1122.	3.3	15
98	Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. Clinical Cancer Research, 2019, 25, 7320-7330.	7.0	14
99	Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug. FASEB Journal, 2001, 15, 1902-1908.	0.5	13
100	Pharmacokinetics of Erlotinib for the Treatment of Highâ€Grade Glioma in a Pediatric Patient with Cystic Fibrosis: Case Report and Review of the Literature. Pharmacotherapy, 2009, 29, 858-866.	2.6	13
101	Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. Cancer, 2020, 126, 4800-4805.	4.1	12
102	Identification of small molecules that mitigate vincristineâ€induced neurotoxicity while sensitizing leukemia cells to vincristine. Clinical and Translational Science, 2021, 14, 1490-1504.	3.1	12
103	Msh2 Deficiency Attenuates But Does Not Abolish Thiopurine Hematopoietic Toxicity inMsh2-/-Mice. Molecular Pharmacology, 2003, 64, 456-465.	2.3	11
104	Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children. Cancer Chemotherapy and Pharmacology, 2006, 57, 475-482.	2.3	11
105	Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma1. Neuro-Oncology, 2006, 8, 89-95.	1.2	11
106	Clinical Pharmacokinetics of Amifostine and WR1065 in Pediatric Patients with Medulloblastoma. Clinical Cancer Research, 2010, 16, 1049-1057.	7.0	11
107	Hypersensitivity reaction to high-dose methotrexate and successful rechallenge in a pediatric patient with osteosarcoma. Pediatric Blood and Cancer, 2014, 61, 373-375.	1.5	11
108	Phase I Study of the Safety and Pharmacokinetics of Plerixafor in Children Undergoing a Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 1224-1228.	2.0	10

#	Article	IF	Citations
109	Incidence of hip and knee osteonecrosis and their associations with bone mineral density in children with acute lymphoblastic leukaemia. British Journal of Haematology, 2020, 189, e177-e181.	2.5	9
110	Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC. Cancer Chemotherapy and Pharmacology, 2005, 55, 433-438.	2.3	8
111	Apoptosome activation, an important molecular instigator in 6-mercaptopurine induced Leydig cell death. Scientific Reports, 2015, 5, 16488.	3.3	8
112	The Heme-Regulated Inhibitor Pathway Modulates Susceptibility of Poor Prognosis B-Lineage Acute Leukemia to BH3-Mimetics. Molecular Cancer Research, 2021, 19, 636-650.	3.4	8
113	A Whole Genome Analysis Identifies SLCO1B1 as a Determinant of Methotrexate Pharmacokinetics and Adverse Effects. Blood, 2008, 112, 214-214.	1.4	8
114	Asparaginase combined with discontinuous dexamethasone improves antileukemic efficacy without increasing osteonecrosis in preclinical models. PLoS ONE, 2019, 14, e0216328.	2.5	7
115	Mathematical modeling of folate metabolism. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2013, 5, 603-613.	6.6	6
116	Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation. Cancer Chemotherapy and Pharmacology, 2020, 86, 711-717.	2.3	6
117	Population Pharmacokinetics of Fludarabine and Treosulfan in Patients with Thalassemia Undergoing Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 3120-3120.	1.4	6
118	Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML. Blood, 2015, 126, 3695-3695.	1.4	6
119	Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates with Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2022, 11, 3316.	2.4	6
120	Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2017, 52, 977-983.	2.4	5
121	Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase. Pediatric Blood and Cancer, 2020, 67, e28244.	1.5	5
122	Limited sampling strategies for accurate determination of extended halfâ€life factor VIII pharmacokinetics in severe haemophilia A patients. Haemophilia, 2021, 27, 408-416.	2.1	5
123	Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase. Cancer Chemotherapy and Pharmacology, 2021, 88, 655-664.	2.3	5
124	Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy. Haematologica, 2022, 107, 371-380.	3.5	5
125	A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1.. Blood, 2012, 120, 2466-2466.	1.4	5
126	Association between obesity and neurocognitive function in survivors of childhood acute lymphoblastic leukemia treated only with chemotherapy. Cancer, 2021, 127, 3202-3213.	4.1	4

#	Article	IF	Citations
127	Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development. EBioMedicine, 2022, 80, 104065.	6.1	4
128	Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatment. Blood, 2020, 136, 2955-2958.	1.4	3
129	Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric Patients with Relapsed/Refractory FLT3+Ve AML. Blood, 2016, 128, 3937-3937.	1.4	3
130	Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome. Blood Advances, 2022, 6, 2824-2834.	5.2	3
131	Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication. Clinical Cancer Research, 2022, 28, 2536-2546.	7.0	3
132	Modelling the Effects of Paclitaxel and Cisplatin on Breast and Ovarian Cancer. Journal of Theoretical Medicine, 2000, 3, 11-23.	0.5	2
133	Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 130-135.e1.	0.4	2
134	Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies. Cancer, 2021, 127, 2074-2082.	4.1	2
135	Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma: A simulation study. Clinical and Translational Science, 2021, 14, 2152-2160.	3.1	2
136	Pegaspargase Allergic Reactions Are Related to Anti-Pegaspargase Antibodies and to Intensity of Intrathecal Therapy. Blood, 2018, 132, 2697-2697.	1.4	2
137	Population Pharmacokinetics of Cyclophosphamide in Patients with Thalassaemia Major Undergoing HSCT Shows Body Weight, CYP450, GST and ALDH Polymorphisms as Covariates Explaining Inter-Individual Variation.. Blood, 2009, 114, 1182-1182.	1.4	2
138	A 5'UTR Polymorphism in NT5E Gene Influences Outcome in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation with Fludarabine Based Conditioning Regimen. Blood, 2016, 128, 984-984.	1.4	2
139	Pharmacokinetics of a Generic Treosulfan in Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, S301-S302.	2.0	1
140	Genetic Variants in Drug Metabolizing and Transporter Genes Explain Variability in Fludarabine Pharmacokinetics in Patients Undergoing HSCT. Biology of Blood and Marrow Transplantation, 2018, 24, S80.	2.0	1
141	Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, S196.	2.0	1
142	Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Determinants of Osteonecrosis In Children with Acute Lymphoblastic Leukemia.. Blood, 2010, 116, 1033-1033.	1.4	1
143	Pharmacokinetics of Cyclophosphamide Metabolites Influence Outcome in Patients with Î²-Thalassemia Major Undergoing Allogeneic HSCT. Blood, 2011, 118, 1941-1941.	1.4	1
144	Clinical Utility and Implications of Asparaginase Antibodies in Acute Lymphoblastic Leukemia. Blood, 2011, 118, 1481-1481.	1.4	1

#	Article	IF	Citations
145	Generic Intravenous Busulfan in Hematopoietic Stem Cell Transplantation: Relevance of Therapeutic Drug Monitoring. Blood, 2015, 126, 4322-4322.	1.4	1
146	Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. Journal of Clinical Investigation, 2005, 115, 477-477.	8.2	0
147	Population Pharmacokinetics of Busulfan in Patients with Beta Thalassaemia Major Undergoing HSCT Reveals Body Weight, GSTA1 and CYP3A4 Promoter Polymorphisms as Main Covariates Explaining the Inter-Individual Variation.. Blood, 2009, 114, 3349-3349.	1.4	0
148	Abstract 2758: Population pharmacokinetics of cyclophosphamide in infants and young children. , 2010, , .		0
149	Systemic Exposure to Dexamethasone and Asparaginase Affects Risk of Relapse in Children with Acute Lymphoblastic Leukemia. Blood, 2011, 118, 2550-2550.	1.4	0
150	Abstract CT409: Dexamethasone (dex) and asparaginase increase triglycerides during acute lymphoblastic leukemia (ALL) therapy in children. , 2014, , .		0
151	Population Pharmacokinetics of Daunorubicin in AML: Influence on Clinical Outcome. Blood, 2014, 124, 902-902.	1.4	0
152	Pharmacokinetics of Fludarabine in Patients with Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 3884-3884.	1.4	0
153	Abstract 4526: Age dependent disposition of cyclophosphamide (CTX) and metabolites in infants â‰¥ 1 year old with brain tumors. , 2015, , .		0
154	Body Mass Index Is Not Associated with Early Treatment Response or Clinical Outcome in Children with Acute Lymphoblastic Leukemia. Blood, 2015, 126, 1299-1299.	1.4	0
155	Asparaginase May Affect Mercaptopurine Tolerability in the Context of Multi-Agent Therapy for Acute Lymphoblastic Leukemia. Blood, 2016, 128, 179-179.	1.4	0
156	The Effect of Asparaginase on Serum Triglycerides during Therapy for Acute Lymphoblastic Leukemia. Blood, 2018, 132, 2665-2665.	1.4	0
157	Treosulfan Metabolite (S, S-EBDM) Pharmacokinetics Influences Regimen Related Toxicity in Patients with Beta Thalassaemia Major Undergoing HSCT. Blood, 2019, 134, 1977-1977.	1.4	0